IDO1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib, used in gastrointestinal stromal tumor (GIST) or chronic myeloid leukemia (CML), can also inhibit IDO expression, by inducing Treg apoptosis and activation of CD8+ T cells [150].